Results 101 to 110 of about 14,812 (260)

Inclusion of Refugees Into National Health Systems: Enablers, Barriers and Lessons From Six Country Case Studies

The International Journal of Health Planning and Management, EarlyView.
ABSTRACT The global refugee population has nearly doubled in the last decade, and many of these populations face chronic displacement, often in neighbouring countries with limited resources. Emergency, short‐term responses are being transitioned to longer term approaches, including a focus on inclusion through coverage in national health systems ...
Sophie Witter, Alastair Ager, Karin Diaconu, Zahid Ali Memon, Ben Ngoye, Natasha Palmer, Marcia Vera‐Espinoza, Amina Olabi, Hussam Rekani, Hassan Ould Moctar, Ricardo Chuquimia, Chitalu Miriam Chama‐Chiliba, Ibrahim Bou‐Orm, Maria Paola Bertone   +13 more
wiley   +1 more source

Reimbursement Design and Procedure‐Level Gross Profit of Robot‐Assisted Gastrectomy in a Publicly Financed Health System: Evidence From Japan

The International Journal of Health Planning and Management, EarlyView.
ABSTRACT Publicly financed healthcare systems must balance technological innovation with fiscal constraints. Reimbursement mechanisms influence institutional decisions regarding the adoption of high‐cost surgical technologies. This study evaluated whether current reimbursement designs adequately reflect procedure‐level gross surgical profit of robot ...
Yoshimasa Akashi, Koichi Ogawa, Yohei Owada, Tsuyoshi Enomoto, Kinji Furuya, Kazuhiro Takahashi, Osamu Shimomura, Yoshihiro Miyazaki, Tatsuya Oda   +8 more
wiley   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, EarlyView.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision‐Making in Dutch Breast Cancer Patients: A Population‐Based Study

International Journal of Cancer, EarlyView.
To avoid unnecessary treatment in breast cancer, several gene expression profiling tests have been developed to help clinicians identify patients who may not benefit from chemotherapy. This study examined the effect of reimbursement availability on the implementation of gene expression profiles using population‐based data from the Netherlands Cancer ...
Joyce Meijer, Nienke Hermanns, Rhodé Bijlsma, Hedwig M. Blommestein, Desiree H. J. G. van den Bongard, Thijs van Dalen, Paul J. van Diest, Caroline A. Drukker, Cristina Guerrero Paez, Aafke H. Honkoop, Agnes Jager, Linetta B. Koppert, Sabine C. Linn, Marissa C. van Maaren, Ester J. Siemerink, Laura J. van ’t, José H. Volders, Marie Jeanne Vrancken Peeters, Sabine Siesling   +18 more
wiley   +1 more source

The Optimal Lung Cancer Ct Screening Strategy: A Cost‐Effectiveness Study Incorporating Nelson Evidence, Evolving Cost of Treatment and Smoking Cessation Interventions

International Journal of Cancer, EarlyView.
ABSTRACT Lung cancer screening implementation is taking shape worldwide. Programme design requires specifying eligibility criteria, screening interval, and the optimal age range. We estimate benefits and harms of competing strategies, integrating NELSON results, smoking cessation interventions, contemporary treatment costs, and the management of ...
Koen de Nijs, Kevin ten Haaf, Dana Moldovanu, Juul Hubert, Isabelle van den Bosch, Carlijn van der Aalst, Harry J. de Koning   +6 more
wiley   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

How Does Vulnerability Framing by Microfinance Institutions Leverage Funding Success in Crowdfunding?

International Journal of Finance &Economics, EarlyView.
ABSTRACT This study draws on framing theory to investigate how microfinance institutions (MFIs) strategically construct a vulnerability‐oriented organisational identity and how this framing influences their funding decisions during the pre‐campaign phase of prosocial crowdfunding.
Ana Paula Matias Gama, Ricardo Emanuel‐Correia, Fábio Duarte, Mário Augusto   +3 more
wiley   +1 more source

Technological Evolution in Fintech: A Decadal Scientometric and Systematic Review of Developments and Criticisms

International Journal of Finance &Economics, EarlyView.
ABSTRACT This study aims to classify pivotal fintech innovations and explore the prospects and pitfalls associated with emerging fintech services extensively discussed in the literature. We conducted a multistage systematic review of research published on fintech over the past decade from a technological perspective. Using the Preferred Reporting Items
Muhammad Imran Qureshi, Nohman Khan
wiley   +1 more source

Environmental Aspects in Price and Reimbursement Decisions of Medicines-A Scoping Review. [PDF]

Basic Clin Pharmacol Toxicol
Alajärvi L, Miettinen M, Timonen J.
europepmc   +1 more source

Innovation incentives and reimbursement schemes in on-patent pharmaceutical markets

, 2023
A presente dissertação analisa de que forma o tipo de inovação escolhido por uma empresa farmacêutica para entrar no mercado, depende da forma como os pacientes são reembolsados pelo regulador nesse setor. A escolha do método de reembolso por parte do regulador afeta a elasticidade preço da procura e por isso os preços praticados.
openaire   +1 more source